Search
Viridian Therapeutics Inc
VRDNAdd to Watchlist
19.890USD
+0.010+0.05%
Close 07-30 16:00（ET）Quotes delayed by 15 min
2.04BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-30The current earnings forecast score of Viridian Therapeutics Inc is 8.71, ranking 75 out of 384 in the Biotechnology & Medical Research industry. The average price target is 40.50, with a high of 50.00 and a low of 19.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
35.333
Target Price
+79.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Viridian Therapeutics Inc
VRDN
17
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Viridian Therapeutics Inc's expected revenue for the next quarter?
Viridian Therapeutics Inc's expected revenue is 22.31K.
What is Viridian Therapeutics Inc's price target?
Analysts forecast that Viridian Therapeutics Inc's price target is USD 40.50, with the highest forecast at USD 50.00 and the lowest forecast at USD 19.00.
How have Viridian Therapeutics IncVRDN's recent earnings per share performed?
The market expectation was USD -1.03, while Viridian Therapeutics IncVRDN's earnings per share (EPS) for the previous quarter was USD -1.27. EPS for the next quarter is expected at USD -1.03.
What is the analyst rating for Viridian Therapeutics Inc?
Based on the ratings of Viridian Therapeutics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.